Ron Peck, M.D.

Ron Peck, M.D. is a medical oncologist and biopharmaceutical leader with 30 years of expertise in oncology drug development. He is founder and principal consultant of Veritas Oncology LLC.

Prior to founding Veritas, Dr. Peck served as Chief Medical Officer at Arvinas during a period of rapid growth in the company’s development activities. He oversaw the advancement of the estrogen receptor degrader vepdegestrant into multiple Phase 3 trials in partnership with Pfizer, the development of two androgen receptor degraders through proof of concept, which led to the licensing of ARV-766 to Novartis, and the initiation of first-in-human studies with two other novel first-in-class PROTAC agents.

Prior to Arvinas, Dr. Peck was SVP, Head of Clinical Research at TESARO Inc. (acquired by GSK) and CMO at Kolltan Pharmaceuticals. Before Kolltan, Dr. Peck spent 15 years at Bristol Myers Squibb in roles of increasing responsibility in clinical research and product development, contributing to the development of drugs such as ipilimumab, ixabepilone, and dasatinib.

Dr. Peck is an adjunct assistant professor in hematology/oncology at Yale University. He earned his M.D. from Thomas Jefferson University and completed his internal medicine residency and fellowship in oncology and hematology at Georgetown University, where he also completed a fellowship in developmental therapeutics.